MK 7288Alternative Names: MK-7288
Latest Information Update: 13 Mar 2014
At a glance
- Originator Merck & Co
- Class Sleep disorder therapies
- Mechanism of Action Histamine H3 receptor inverse agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Sleep apnoea syndrome
Most Recent Events
- 01 May 2013 No development reported - Phase-I for Sleep apnoea syndrome in USA (PO)